Researchers have identified a rare type of immune cell, called stem-like T cells, that plays a crucial role in maintaining long-term immune responses against cancer and chronic infections. These findings could open new doors for improving immunotherapy treatments and strengthening immune defenses in patients suffering from prolonged illnesses. The study was conducted by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and the Peter MacCallum Cancer Centre (Peter Mac) and was published in Science Immunology.

Chronic diseases like cancer and persistent infections often leave the immune system in a state of exhaustion, where T cells, the body’s primary immune defenders, lose their effectiveness over time. However, the researchers discovered that ID3+ T cells, a subtype of stem-like T cells, possess a unique ability to self-renew and resist exhaustion. These cells are regulated by a protein called ID3, which is encoded by the ID3 gene. The presence of ID3 allows these cells to sustain immune responses much longer than other T cells that do not express this protein, making them a potential game-changer in the treatment of chronic diseases.

According to Catarina Gago da Graca, a PhD Candidate at the Doherty Institute and co-first author of the study, ID3+ T cells hold the key to overcoming one of the biggest challenges in treating chronic diseases—immune exhaustion. Unlike other T cells that deteriorate under prolonged stress, these stem-like T cells can maintain their function over extended periods. This discovery provides valuable insights into how the immune system can be reinforced against long-term illnesses.

Further research found that certain biological signals can enhance the formation of ID3+ T cells, increasing their numbers and effectiveness. This could have significant implications for CAR T cell therapy, an advanced form of immunotherapy used in cancer treatment. By boosting ID3 activity, scientists believe they can strengthen the endurance of these immune cells, making cancer therapies more effective and long-lasting.

Professor Ricky Johnstone, Executive Director of Cancer Research at Peter Mac and co-lead author of the study, emphasized that enhancing ID3 activity could significantly improve cancer treatments. The study suggests that specific inflammatory cues in the body can trigger the production of ID3+ T cells, providing a potential pathway to increase immune resilience in cancer patients. This could lead to more successful clinical outcomes for immunotherapy treatments.

Additionally, Dr. Daniel Utzschneider, Laboratory Head at the Doherty Institute, stated that these findings could contribute to the development of vaccines that offer long-lasting immunity. By understanding how to sustain immune responses using ID3+ T cells, researchers hope to develop more durable and effective immunotherapies for both infectious diseases and cancer.

This groundbreaking study was a collaborative effort involving leading research institutions, including the Doherty Institute, Peter Mac, La Trobe University, Northwestern University (USA), the Olivia Newton-John Cancer Research Institute, the University of Birmingham (UK), and the University of Melbourne. Their collective efforts bring new hope for strengthening immune responses and improving patient outcomes in the fight against chronic diseases.

Disclaimer:

The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.

Write A Comment

14 + 9 =

      SUBSCRIBE NEWS LETTER

By navigating our site, you agree to allow us to use cookies, in accordance with our Privacy Policy.